Skip to main content

Advertisement

SpringerLink
Log in

Metastatic gastrointestinal stromal tumors

  • Supplement (SPECIAL ISSUE)
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Sircar K, Hewlett BR, Huizinga JD et al (1999) Interstitial cells of Cajal as precursors of gastrointestinal stromal tumors. Am J Surg Pathol 23:377–389

    Article  CAS  PubMed  Google Scholar 

  2. Hirota S, Isozaki K, Moriyama Y et al (1998) Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 279:577–580

    Article  CAS  PubMed  Google Scholar 

  3. Yarden Y, Kuang W-J, Yang-Feng T et al (1987) Human proto-oncogene c-kit: a new cell surface receptor tyrosine kinase for an unidentified ligand. EMBO J 6:3341–3351

    CAS  PubMed  Google Scholar 

  4. Rubin BP, Singer S, Tsao C et al (2001) KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res 61:8118–8121

    CAS  PubMed  Google Scholar 

  5. Heinrich MC, Corless CL, Demetri GD et al (2003) Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 21:4342–4349

    Article  CAS  PubMed  Google Scholar 

  6. Debiec-Rychter M, Sciot R, Le Cesne A et al (2006) KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer 42:1093–1103

    Article  CAS  PubMed  Google Scholar 

  7. Heinrich MC, Owzar K, Corless CL et al (2008) Correlation of kinase genotype and clinical outcome in the North American Intergroup phase III trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 study by Cancer and Leukemia Group B and Southwest Oncology Group. J Clin Oncol 26:5360–5367

    Article  CAS  PubMed  Google Scholar 

  8. Heinrich MC, Corless CL, Duensing A et al (2003) PDGFRA activating mutations in gastrointestinal stromal tumors. Science 299:708–710

    Article  CAS  PubMed  Google Scholar 

  9. Corless CL, Schroeder A, Griffith D et al (2005) PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib. J Clin Oncol 23:5357–5364

    Article  CAS  PubMed  Google Scholar 

  10. Agaram NP, Wong GC, Guo T et al (2008) Novel V600E BRAF mutations in imatinib-naïve and imatinib-resistant gastrointestinal stromal tumors. Genes, Chromosomes Cancer 47:853–859

    Article  CAS  PubMed  Google Scholar 

  11. Agaimy A, Terracciano LM, Dirnhofer S et al (2009) V600E BRAF mutations are alternative early molecular events in a subset of KIT/PDGFRA wild-type gastrointestinal stromal tumours. J Clin Pathol 62:613–616

    Article  CAS  PubMed  Google Scholar 

  12. Corless CL, McGreevey L, Haley A et al (2002) KIT mutations are common in incidental gastrointestinal stromal tumors one centimeter or less in size. Am J Pathol 160:1567–1572

    CAS  PubMed  Google Scholar 

  13. Kawanowa K, Sakuma Y, Sakurai S et al (2006) High incidence of microscopic gastrointestinal stromal tumors in the stomach. Hum Pathol 37:1527–1535

    Article  PubMed  Google Scholar 

  14. El-Rifai W, Sarlomo-Rikala M, Andersson LC et al (2000) DNA sequence copy number changes in gastrointestinal stromal tumors: tumor progression and prognostic significance. Cancer Res 60:3899–3903

    CAS  PubMed  Google Scholar 

  15. Miettinen M, Lasota J (2006) Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol 23:70–83

    Article  PubMed  Google Scholar 

  16. Gold JS, van der Zwan SM, Gönen M et al (2007) Outcome of metastatic GIST in the era before tyrosine kinase inhibitors. Ann Surg Oncol 14:134–142

    Article  PubMed  Google Scholar 

  17. Blanke CD, Rankin C, Demetri GD et al (2008) Phase III randomized, Intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the Kit receptor tyrosine kinase: S0033. J Clin Oncol 26:626–632

    Article  CAS  PubMed  Google Scholar 

  18. Blanke CD, Demetri GD, von Mehren M et al (2008) Long-term results from a randomized phase II trial of standard-versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol 26:620–625

    Article  CAS  PubMed  Google Scholar 

  19. Rutkowski P, Nowecki ZI, Debiec-Rychter M et al (2007) Predictive factors for long-term effects of imatinib therapy in patients with inoperable/metastatic CD117 + gastrointestinal stromal tumors (GISTs). J Cancer Res Clin Oncol 133:589–597

    Article  CAS  PubMed  Google Scholar 

  20. Heinrich MC, Griffith DJ, Druker BJ et al (2000) Inhibition of c-kit receptor kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood 96:925–932

    CAS  PubMed  Google Scholar 

  21. Joensuu H, Roberts PJ, Sarlomo-Rikala M et al (2001) Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 344:1052–1056

    Article  CAS  PubMed  Google Scholar 

  22. Van Oosterom AT, Judson I, Verweij J et al (2001) Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet 358:1421–1423

    Article  PubMed  Google Scholar 

  23. Demetri GD, von Mehren M, Blanke CD et al (2002) Efficacy and safety of imatinb mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347:472–480

    Article  CAS  PubMed  Google Scholar 

  24. Verweij J, Casali PG, Kotasek D et al (2007) Imatinib does not induce cardiac left ventricular failure in gastrointestinal stromal tumours patients: analysis of EORTC-ISG-AGITG study 62005. Eur J Cancer 43:974–978

    Article  CAS  PubMed  Google Scholar 

  25. Verweij J, van Oosterom A, Blay J-Y et al (2003) Imatinib mesylate is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft tissue sarcomas that are unselected for molecular target: results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study. Eur J Cancer 39:2006–2011

    Article  CAS  PubMed  Google Scholar 

  26. Verweij J, Casali PG, Zalcberg J et al (2004) Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 364:1127–1134

    Article  CAS  PubMed  Google Scholar 

  27. Gastrointestinal Stromal Tumor Meta-Analysis Group (MetaGIST) (2010) Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a meta-analysis of 1640 patients. J Clin Oncol 28:1247–1253

    Article  Google Scholar 

  28. Blay JY, Le Cesne A, Ray-Coquard I et al (2007) Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group. J Clin Oncol 25:1107–1113

    Article  CAS  PubMed  Google Scholar 

  29. Adenis A, Cassier PA, Bui BN et al (2008) Does interruption of imatinib in responding patients after three years of treatment influence outcome of patients with advanced GIST included in the BFR 14 trial? Proc Am Soc Clin Oncol (abstr 10522)

  30. Bechtold RE, Chen MYM, Stanton CA et al (2003) Cystic changes in hepatic and peritoneal metastases from gastrointestinal stromal tumors treated with Gleevec. Abdom Imaging 28:808–814

    Article  CAS  PubMed  Google Scholar 

  31. Antoch G, Kanja J, Bauer S et al (2004) Comparison of PET, CT, and dual-modality PET/CT imaging for monitoring of imatinib (STI571) therapy in patients with gastrointestinal stromal tumors. J Nucl Med 45:357–365

    CAS  PubMed  Google Scholar 

  32. Eisenberg BL, Harris J, Blanke CD et al (2009) Phase II trial of neoadjuvant/adjuvant imatinib mesylate for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor: early results of RTOG 0132/ACRIN 6665. J Surg Oncol 99:42–47

    Article  CAS  PubMed  Google Scholar 

  33. Raut CP, Posner M, Desai J et al (2006) Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors. J Clin Oncol 24:2325–2331

    Article  CAS  PubMed  Google Scholar 

  34. DeMatteo RP, Maki RG, Singer S et al (2007) Results of tyrosine kinase inhibitor therapy followed by surgical resection for metastatic gastrointestinal stromal tumor. Ann Surg 245:347–352

    Article  PubMed  Google Scholar 

  35. Gronchi A, Fiore M, Miselli F et al (2007) Surgery of residual disease following molecular-targeted therapy with imatinib mesylate in advanced/metastatic GIST. Ann Surg 245:341–346

    Article  PubMed  Google Scholar 

  36. Heinrich MC, Corless CL, Blanke CD et al (2006) Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J Clin Oncol 24:4764–4774

    Article  CAS  PubMed  Google Scholar 

  37. Zalcberg JR, Verweij J, Casali PG et al (2005) Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg. Eur J Cancer 41:1751–1757

    Article  CAS  PubMed  Google Scholar 

  38. Demetri GD, van Oosterom AT, Garrett CR et al (2006) Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomized controlled trial. Lancet 368:1329–1338

    Article  CAS  PubMed  Google Scholar 

  39. Chu TF, Rupnick MA, Kerkela R et al (2007) Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet 370:2011–2019

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

Logistical support during submission of this article was provided by Springer Healthcare LLC. This support was funded by Novartis.

Conflict of interest

Francine Aubin: No conflicts of interest. Charles D. Blanke: Novartis.

Author information

Authors and Affiliations

  1. Centre Hospitalier de l’Université de Montréal (CHUM), Notre-Dame Hospital, 1560 Sherbrooke Est, Montreal, QC H2L 4M1, Canada

    Francine Aubin

  2. Division of Medical Oncology, University of British Columbia and British Columbia Cancer Agency, Vancouver, Canada

    Charles D. Blanke

Authors
  1. Francine Aubin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Charles D. Blanke
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Charles D. Blanke.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Aubin, F., Blanke, C.D. Metastatic gastrointestinal stromal tumors. Cancer Chemother Pharmacol 67 (Suppl 1), 9–14 (2011). https://doi.org/10.1007/s00280-010-1512-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00280-010-1512-9

Keywords

Search

Navigation